title: Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus.
abstract: OBJECTIVE
  Endoscopic therapy is emerging as an alternative to surgical therapy in patients with mucosal (T1a) esophageal adenocarcinoma (EAC) given the low likelihood of lymph node metastases. Long-term outcomes of patients treated endoscopically and surgically for mucosal EAC are unknown. We compared long-term outcomes of patients with mucosal EAC treated endoscopically and surgically.
  
  
  METHODS
  Patients treated for mucosal EAC between 1998 and 2007 were included. Patients were divided into an endoscopically treated group (ENDO group) and a surgically treated group (SURG group). Vital status information was queried using an institutionally approved internet research and location service. Statistical analysis was performed using Kaplan-Meier curves and Cox proportional hazard ratios.
  
  
  RESULTS
  A total of 178 patients were included, of whom 132 (74%) were in the ENDO group and 46 (26%) were in the SURG group. The mean follow-up period was 64 months (standard error of the mean, 4.8 mo) in the SURG group and 43 months (standard error of the mean, 2.8 mo) in the ENDO group. Cumulative mortality in the ENDO group (17%) was comparable with the SURG group (20%) (P = .75). Overall survival also was comparable using the Kaplan-Meier method. Treatment modality was not a significant predictor of survival on multivariable analysis. Recurrent carcinoma was detected in 12% of patients in the ENDO group, all successfully re-treated without impact on overall survival.
  
  
  CONCLUSIONS
  Overall survival in patients with mucosal EAC when treated endoscopically appears to be comparable with that of patients treated surgically. Recurrent carcinoma occurs in a limited proportion of patients, but can be managed endoscopically.
authors.affiliation: Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
authors.forename: Ganapathy A
authors.initials: GA
authors.lastname: Prasad
authors.forename: Tsung Teh
authors.initials: TT
authors.lastname: Wu
authors.forename: Dennis A
authors.initials: DA
authors.lastname: Wigle
authors.forename: Navtej S
authors.initials: NS
authors.lastname: Buttar
authors.forename: Louis-Michel
authors.initials: LM
authors.lastname: Wongkeesong
authors.forename: Kelly T
authors.initials: KT
authors.lastname: Dunagan
authors.forename: Lori S
authors.initials: LS
authors.lastname: Lutzke
authors.forename: Lynn S
authors.initials: LS
authors.lastname: Borkenhagen
authors.forename: Kenneth K
authors.initials: KK
authors.lastname: Wang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D000368:Aged; D001471:Barrett Esophagus / Q000150:complications*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D016629:Esophagectomy; D004945:Esophagoscopy; D005260:Female; D006801:Humans; D008297:Male; D009092:Mucous Membrane; D009364:Neoplasm Recurrence, Local; D010778:Photochemotherapy; D054328:Proton Pump Inhibitors / Q000627:therapeutic use
chemical_list: D054328:Proton Pump Inhibitors